| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BCL9 |
| Uniprot No | O00512 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 174-396aa |
| 氨基酸序列 | AKVVYVFSTEMANKAAEAVLKGQVETIVSFHIQNISNNKTERSTAPLNTQISALRNDPKPLPQQPPAPANQDQNSSQNTRLQPTPPIPAPAPKPAAPPRPLDRESPGVENKLIPSVGSPASSTPLPPDGTGPNSTPNNRAVTPVSQGSNSSSADPKAPPPPPVSSGEPPTLGENPDGLSQEQLEHRERSLQTLRDIQRMLFPDEKEFTGAQSGGPQQNPGVLD |
| 预测分子量 | 26.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BCL9重组蛋白的3篇参考文献及其简要摘要：
1. **文献名称**：*Targeting BCL9-mediated β-catenin transcriptional complex signaling overcomes immune resistance in anti-PD-1 therapy*
**作者**：Li J, et al.
**摘要**：该研究通过重组BCL9蛋白探索其与β-catenin复合物的相互作用，发现抑制BCL9可增强抗PD-1治疗的免疫响应，为克服肿瘤免疫耐药性提供新策略。
2. **文献名称**：*Structural basis of BCL9 recognition by β-catenin in the Wnt signaling pathway*
**作者**：Sampietro J, et al.
**摘要**：利用重组BCL9蛋白进行结构生物学分析，揭示了BCL9与β-catenin结合的分子机制，阐明其在Wnt信号通路中的关键作用，为靶向药物设计提供结构基础。
3. **文献名称**：*BCL9 promotes tumor progression by conferring cancer stem-like properties in colorectal cancer*
**作者**：Zhang Y, et al.
**摘要**：通过重组BCL9蛋白功能实验，证明其通过激活Wnt/β-catenin通路增强结直肠癌干性特征，促进肿瘤侵袭和转移，提示BCL9作为潜在治疗靶点。
(注：以上文献信息为示例，实际引用需核对原文准确性。)
BCL9 (B-cell lymphoma 9) is a transcriptional co-activator protein that plays a critical role in the Wnt/β-catenin signaling pathway, a key regulatory system involved in embryonic development, tissue homeostasis, and cancer progression. It was initially identified through its association with chromosomal translocations in B-cell lymphomas, though its oncogenic functions are most studied in solid tumors, particularly colorectal and hepatocellular carcinomas. BCL9 interacts with β-catenin and Pygopus (Pygo) to form a ternary complex that stabilizes nuclear β-catenin, enabling the transcription of Wnt target genes linked to cell proliferation, survival, and metastasis.
Recombinant BCL9 proteins are engineered to study molecular mechanisms of Wnt signaling dysregulation. These proteins are typically expressed in bacterial or mammalian systems, often tagged with affinity markers (e.g., His, GST) for purification and detection. Structural studies using recombinant BCL9 have mapped critical domains, such as the HD1 and HD2 regions responsible for β-catenin and Pygo binding, respectively. Researchers also design truncated or mutated variants (e.g., dominant-negative forms) to disrupt the BCL9-β-catenin interaction, aiming to inhibit oncogenic Wnt activity in preclinical models.
Therapeutic interest in BCL9 stems from its overexpression in cancers with hyperactive Wnt pathways. Recombinant BCL9 serves as a tool for drug screening, structural analysis, and functional assays to develop peptide inhibitors or small molecules targeting this interaction. Challenges include optimizing protein stability and solubility due to its intrinsically disordered regions. Current studies focus on clarifying its context-dependent roles in tumor microenvironments and resistance mechanisms, underscoring its potential as a biomarker or therapeutic target in precision oncology.
×
